Sees $4.5B-$5.0B operating cash flow, $1.5B-$1.7B capex, $3.0B-$3.3B in free cash flow and about $0.7B in share buybacks. Longer term outlook assumed 7%-9% EPS CAGR and 4%-5% total revenue growth CAGR. Comments taken from investor presentation slides disclosed in regulatory 8-K filing ahead of the company’s JP Morgan Health Care Conference presentation.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX: